Valturna patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168616 NOVARTIS Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
Jul, 2026

(2 years from now)

Valturna is owned by Novartis.

Valturna contains Aliskiren Hemifumarate; Valsartan.

Valturna has a total of 1 drug patent out of which 0 drug patents have expired.

Valturna was authorised for market use on 16 September, 2009.

Valturna is available in tablet;oral dosage forms.

The generics of Valturna are possible to be released after 03 July, 2026.

Drugs and Companies using ALISKIREN HEMIFUMARATE; VALSARTAN ingredient

Market Authorisation Date: 16 September, 2009

Treatment: NA


More Information on Dosage

VALTURNA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic